Padma-28, et urtepraeparat, øger gangdistancen hos patienter med claudicatio intermittens
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Padma-28, et urtepraeparat, øger gangdistancen hos patienter med claudicatio intermittens. / Drabaek, H; Mehlsen, J; Petersen, J R; Himmelstrup, H; Hansen, K F.
In: Ugeskrift for Laeger, Vol. 156, No. 42, 17.10.1994, p. 6207-9.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Padma-28, et urtepraeparat, øger gangdistancen hos patienter med claudicatio intermittens
AU - Drabaek, H
AU - Mehlsen, J
AU - Petersen, J R
AU - Himmelstrup, H
AU - Hansen, K F
PY - 1994/10/17
Y1 - 1994/10/17
N2 - Thirty-six patients with stable intermittent claudication were randomized in a doubleblind study either to treatment with two tablets of Padma-28 twice daily (containing 340 mg dried herbal mixture composed according to an ancient lamaistic prescription) or placebo for four months. Effect of treatment was quantified by measurements of systemic and peripheral systolic blood pressures, and pain-free and maximal walking distances on a tread-mill. The actively treated group attained a significant increase in pain-free walking distance from 115 m (72-218) to 227 m (73- >1000, p <0.05). The placebo group did not show significant changes in either pain-free or maximal walking distance. Significant changes in systemic or peripheral blood pressures could not be demonstrated in any of the groups. In conclusion, our study has shown that treatment with Padma-28 over a four month period significantly increases the walking distance in patients with stable intermittent claudication of long duration.
AB - Thirty-six patients with stable intermittent claudication were randomized in a doubleblind study either to treatment with two tablets of Padma-28 twice daily (containing 340 mg dried herbal mixture composed according to an ancient lamaistic prescription) or placebo for four months. Effect of treatment was quantified by measurements of systemic and peripheral systolic blood pressures, and pain-free and maximal walking distances on a tread-mill. The actively treated group attained a significant increase in pain-free walking distance from 115 m (72-218) to 227 m (73- >1000, p <0.05). The placebo group did not show significant changes in either pain-free or maximal walking distance. Significant changes in systemic or peripheral blood pressures could not be demonstrated in any of the groups. In conclusion, our study has shown that treatment with Padma-28 over a four month period significantly increases the walking distance in patients with stable intermittent claudication of long duration.
M3 - Tidsskriftartikel
VL - 156
SP - 6207
EP - 6209
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 42
ER -
ID: 34073762